Important Security Class Action Reminder for Aquestive Therapeutics Investors: Deadline Approaching

Important Notice for Investors

As the deadline of May 4, 2026 approaches, investors in Aquestive Therapeutics, Inc. should take heed. Faruqi & Faruqi, LLP, a respected national securities law firm, is urging those who have acquired shares of Aquestive between June 16, 2025, and January 8, 2026, to consider their legal rights. In particular, those who feel affected by recent corporate actions must act quickly to secure their potential for recovery.

Faruqi & Faruqi has initiated a comprehensive investigation into the claims against Aquestive, which trades under the stock symbol AQST. Allegations detail that the company violated federal securities laws by making misleading statements regarding its New Drug Application (NDA) for Anaphylm. The firm asserts that during a crucial period, the company downplayed significant details regarding the human factors involved in the usage and deployment of their sublingual film, notably in aspects such as packaging, application, and labeling. These omissions may have misled investors about the product's viability.

On January 9, 2026, the situation took a turn when the President and CEO of Aquestive announced that the FDA uncovered deficiencies in the NDA that precluded further discussions on labeling and post-marketing commitments. As a result of this news, the stock plummeted by over 37%, emphasizing the urgency for investors to evaluate their options.

Faruqi & Faruqi's approach centers on representing affected investors, providing direction on how to become a lead plaintiff in the ongoing litigation, and ensuring that voices of shareholders are heard in the courtroom. The lead plaintiff plays a critical role, guiding litigation on behalf of the larger class of affected investors and would need to possess the largest financial stake in the matter.

Anyone wishing to step forward can take action through their counsel of choice or remain a passive class member without losing their recovery potential. Faruqi & Faruqi also welcomes anyone who has pertinent information about the company's practices—including whistleblowers and former employees—to reach out for further discussions.

For those who may feel the consequences of these legal issues, the time to act is now. You can gather more information regarding potential claims at www.faruqilaw.com/AQST or directly call Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). In doing so, you'll be taking essential steps to ensure that your voice is part of this pivotal conversation.

As we draw closer to the approaching deadline, remaining informed and proactive is paramount. Don't miss out on the opportunity to protect your investments and secure your rights as an investor.

Faruqi & Faruqi, LLP remains committed to advocating for investors' rights, having recovered hundreds of millions in losses for investors since its inception in 1995. As they continue this mission, keeping vigilant on your investments and any actions surrounding them is vital for your financial health.